Anthropic Opens Physical Biology Lab for AI Drug Research

Anthropic expands beyond computational AI into physical experimentation

Anthropic has established a wet lab in the San Francisco Bay Area where it conducts physical biology experiments, marking a significant expansion of the AI company's push into drug research and development.

Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the lab's existence in an interview with Reuters. "We believe that to do biology, the final test is still and will be for a while in real lab work," he said. "We absolutely are doing that today." An Anthropic spokesperson later clarified that while the lab exists, it is not exclusively dedicated to drug discovery, though the company declined to provide additional details.

The facility represents Anthropic's commitment to moving beyond purely computational research as it works to develop treatments for diseases that traditional pharmaceutical companies have deemed financially unattractive.

Automation and robotics integration

Anthropic is exploring whether its Claude AI system can direct robotic laboratory equipment to execute experiments with minimal human staffing, according to two people familiar with the matter. The company is following broader biotech industry trends by incorporating physical automation into its operations.

However, Anthropic emphasized that human oversight remains mandatory for safety. "We're in the very early innings of using AI to automate the execution of lab work," Kauderer-Abrams said.

Rapid buildout of life sciences capabilities

The physical lab is part of a broader life sciences expansion at Anthropic. The company has launched Claude Science, a research workbench that connects to over 60 scientific databases with specialized toolkits for genomics, proteomics, and structural biology. Anthropic also acquired Coefficient Bio for approximately $400 million in stock to advance its drug development capabilities.

On the governance side, Anthropic added Novartis CEO Vas Narasimhan to its board. The life sciences division has grown into one of the company's most heavily staffed and resourced departments, according to Kauderer-Abrams.

Pharma partnerships and strategic boundaries

Anthropic has established collaborations with several major pharmaceutical companies. This week, the company announced a partnership with Novo Nordisk aimed at accelerating drug discovery using Claude. It previously reached an agreement giving Bristol-Myers Squibb workforce access to Claude for research and development, and is providing AI services to Roche's Genentech.

Kauderer-Abrams stressed that Anthropic is not positioning itself as a competitor to pharmaceutical and biotech companies. "We're not competing with pharma and biotech companies that make their business in bringing drugs to market," he said. The company has set a clear boundary against running clinical trials for now.

Why it matters

Anthropic's move into physical laboratory work signals a strategic bet that AI companies must integrate wet-lab experimentation to make meaningful contributions to drug discovery. By focusing on rare diseases that lack commercial appeal for traditional pharma, Anthropic is carving out a niche where AI-driven efficiency could unlock treatments that might otherwise never be developed. The approach also tests whether frontier AI models can effectively bridge the gap between computational biology and physical experimentation—a capability that could reshape early-stage drug research if successful.

Anthropic first signaled its drug program ambitions at a June gathering in San Francisco, where Kauderer-Abrams told attendees the company would concentrate on early-stage research in areas established industry players had passed over for financial reasons.

These details were first reported by Reuters and CNBC.